Format

Send to

Choose Destination
Cancer J. 2010 Jul-Aug;16(4):336-41. doi: 10.1097/PPO.0b013e3181eb3879.

Adoptive cell therapy: genetic modification to redirect effector cell specificity.

Author information

1
Surgery Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA. rmorgan@mail.nih.gov

Abstract

Building on the principals that the adoptive transfer of T cells can lead to the regression of established tumors in humans, investigators are now further manipulating these cells using genetic engineering. Two decades of human gene transfer experiments have resulted in the translation of laboratory technology into robust clinical applications. The purpose of this review is to give the reader an introduction to the 2 major approaches being developed to redirect effector T-cell specificity. Primary human T cells can be engineered to express exogenous T-cell receptors or chimeric antigen receptors directed against multiple human tumor antigens. Initial clinical trial results have demonstrated that both T-cell receptor- and chimeric antigen receptor-engineered T cells can be administered to cancer patients and mediate tumor regression.

PMID:
20693844
DOI:
10.1097/PPO.0b013e3181eb3879
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center